Nearly half of CBD products tested had inaccurate labels

Testing of 80 commercial CBD products found that 46% had CBD concentrations more than 10% off from their label claims, with some products containing less than half the advertised amount.

Johnson, Erin et al.·Journal of cannabis research·2022·Strong EvidenceObservational
RTHC-03939ObservationalStrong Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Of 80 products, 37 (46%) contained CBD concentrations more than 10% different from label claims. Discrepancies ranged from 0.9 to 30.6 mg/mL off from the label. 12 products were underlabeled (more than 110% of claim) and 25 were overlabeled (less than 90% of claim). Overall concordance within 10% tolerance was only 54%.

Key Numbers

80 products tested. Label claims: 7.5-60 mg/mL. Measured: 2.9-61.3 mg/mL. 37 products (46%) outside 10% tolerance. 25 overlabeled (too little CBD), 12 underlabeled (too much). Concordance rate: 54%.

How They Did This

LC-MS/MS analysis of 80 commercially available hemp-derived CBD products from online and local retailers in central Kentucky. CBD concentrations were compared to label claims. Epidiolex included as a regulated positive control.

Why This Research Matters

When nearly half of CBD products contain the wrong amount, consumers cannot reliably dose. Too little means no benefit; too much risks drug interactions and liver enzyme elevations.

The Bigger Picture

The CBD industry's labeling accuracy problem is not improving. Without good manufacturing practices and mandatory testing standards, consumers have little way to know what they are actually taking.

What This Study Doesn't Tell Us

Products from one geographic area. Single time point. Did not assess whether labeling accuracy varied by price point, brand type, or sales channel. Epidiolex as the only regulated comparator.

Questions This Raises

  • ?Would third-party testing requirements improve label accuracy?
  • ?Do consumers who think CBD "doesn't work" simply have underdosed products?

Trust & Context

Key Stat:
46% of products mislabeled; only 54% concordance
Evidence Grade:
Validated analytical methods with appropriate sample size of commercial products and a regulated control.
Study Age:
Published in 2022.
Original Title:
Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim.
Published In:
Journal of cannabis research, 4(1), 28 (2022)
Database ID:
RTHC-03939

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

Are CBD product labels accurate?

In this study, only 54% of 80 CBD products had CBD concentrations within 10% of their label claims. Some contained less than half the advertised amount.

What are the risks of inaccurate CBD labels?

Underdosed products may provide no therapeutic benefit, while overdosed products increase the risk of side effects, drug interactions, and liver enzyme elevations.

Read More on RethinkTHC

Cite This Study

RTHC-03939·https://rethinkthc.com/research/RTHC-03939

APA

Johnson, Erin; Kilgore, Michael; Babalonis, Shanna. (2022). Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim.. Journal of cannabis research, 4(1), 28. https://doi.org/10.1186/s42238-022-00140-1

MLA

Johnson, Erin, et al. "Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim.." Journal of cannabis research, 2022. https://doi.org/10.1186/s42238-022-00140-1

RethinkTHC

RethinkTHC Research Database. "Label accuracy of unregulated cannabidiol (CBD) products: me..." RTHC-03939. Retrieved from https://rethinkthc.com/research/johnson-2022-label-accuracy-of-unregulated

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.